SCHEMBL6896843

SCHEMBL6896843

CCOC(=O)c1nc(C)ccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
CYP1A2 P05177 3/20 0.49
HSD17B10 Q99714 2/20 0.49
GRM5 P41594 1/20 0.48
LMNA P02545 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAOA P21397 1/20 0.47
HTT P42858 1/20 0.46
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
HPGD P15428 1/20 0.43
TARBP2 Q15633 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31282770 1.00 ALDH1A1 (0.49) ALDH1A1CYP1A2HSD17B10GRM5LMNA
SCHEMBL22140520 0.86 ALDH1A1 (0.49) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL22140360 0.85 ALDH1A1 (0.47) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL31283683 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL31122089 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL4905420 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL22140361 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL31163561 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL7453018 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4
SCHEMBL2032423 0.83 ALDH1A1 (0.46) ALDH1A1CYP1A2HSD17B10LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102844302-A Nitrogen-containing heterocyclic compound and method for producing same NIPPON SODA CO 2012-12-26 CN claimed
EP-4472963-A1 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. (US) 2024-12-11 EP disclosed
CN-118946556-A DGK targeting compounds and uses thereof 阿维纳斯运营公司 2024-11-12 CN disclosed
WO-2023150186-A1 DGK TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2023-08-10 WO disclosed
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
CN-102844302-B Nitrogen-containing heterocyclic compound and method for producing same NIPPON SODA CO 2014-07-09 CN disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
CN-102844302-A Nitrogen-containing heterocyclic compound and method for producing same NIPPON SODA CO 2012-12-26 CN disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed
WO-2011089132-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 WO disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 ALDH1A1 703/4885CYP1A2 1906/4885HSD17B10 2122/4885
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A ALDH1A1 271/4885CYP1A2 186/4885HSD17B10 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.